See the DrugPatentWatch profile for Amitiza
What is Amitiza 24 mcg capsule used for?
Amitiza 24 mcg capsule, containing lubiprostone, is a medication used for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) [1]. It works by increasing fluid secretion in the intestines, helping to soften stools and improve bowel movements.
How does Amitiza 24 mcg capsule work?
Lubiprostone, the active ingredient in Amitiza, is a locally acting chloride channel activator that increases the secretion of chloride ions into the intestines [2]. This increase in chloride ions helps to soften stool and improve bowel function.
Common side effects of Amitiza 24 mcg capsule
The most common side effects of Amitiza 24 mcg capsule include nausea, diarrhea, abdominal discomfort, and vomiting [3]. These side effects are usually mild to moderate in severity and typically subside on their own within a few days.
When to seek medical attention
If you experience severe or persistent side effects, such as vomiting, diarrhea, or abdominal pain, or if you have a history of kidney or liver disease, you should consult your doctor or healthcare provider before taking Amitiza 24 mcg capsule [4].
Patent information
The patent for Amitiza 24 mcg capsule, or lubiprostone, is owned by Takeda Pharmaceutical Company Limited [5]. According to DrugPatentWatch.com, the patent for lubiprostone in the United States expired on April 17, 2019, which has allowed generic versions of the medication to enter the market [6].
Generic versions of Amitiza 24 mcg capsule
Generic versions of lubiprostone, including Amitiza 24 mcg capsule, have been approved by the FDA, providing a more affordable alternative to the brand-name medication [7].
References
[1] Takeda Pharmaceutical Company Limited. (2020). Amitiza Prescribing Information.
[2] DrugPatentWatch.com. (2020). Lubiprostone Patents.
[3] Takeda Pharmaceutical Company Limited. (2020). Amitiza Prescribing Information.
[4] Takeda Pharmaceutical Company Limited. (2020). Amitiza Prescribing Information.
[5] Takeda Pharmaceutical Company Limited. (2020). Amitiza Prescribing Information.
[6] DrugPatentWatch.com. (2020). Lubiprostone Patents.
[7] FDA. (2020). Approval Letter for Generic Lubiprostone.